Drug Profile
Terbutaline modified-release - Vectura
Alternative Names: SKP-1052Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator SkyePharma PLC
- Developer Vectura
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Small molecules; Tocolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypoglycaemia
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Hypoglycaemia(Prevention) in Germany (PO, Tablet)
- 08 Sep 2016 Terbutaline modified-release is still in phase I development for Hypoglycaemia (Prevention) (Skyepharma Pipeline, September 2016)
- 02 Sep 2011 Terbutaline modified-release - Skye Pharma is available for licensing as of 02 Sep 2011.